IN2015DN03026A - - Google Patents

Info

Publication number
IN2015DN03026A
IN2015DN03026A IN3026DEN2015A IN2015DN03026A IN 2015DN03026 A IN2015DN03026 A IN 2015DN03026A IN 3026DEN2015 A IN3026DEN2015 A IN 3026DEN2015A IN 2015DN03026 A IN2015DN03026 A IN 2015DN03026A
Authority
IN
India
Prior art keywords
elicit
hiv
fragments
recognized
naturally occurring
Prior art date
Application number
Other languages
English (en)
Inventor
Phillip W ; Berman
Gwen; Tatsuno
Bin; Yu
Javier; Morales
Kathryn; Mesa
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IN2015DN03026A publication Critical patent/IN2015DN03026A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN3026DEN2015 2012-09-11 2013-09-11 IN2015DN03026A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699680P 2012-09-11 2012-09-11
PCT/US2013/059243 WO2014043220A2 (en) 2012-09-11 2013-09-11 Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies

Publications (1)

Publication Number Publication Date
IN2015DN03026A true IN2015DN03026A (enExample) 2015-10-02

Family

ID=50278843

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3026DEN2015 IN2015DN03026A (enExample) 2012-09-11 2013-09-11

Country Status (7)

Country Link
US (2) US9731002B2 (enExample)
EP (1) EP2928492A4 (enExample)
CN (1) CN106170296A (enExample)
AU (1) AU2013315631B2 (enExample)
CA (1) CA2929937C (enExample)
IN (1) IN2015DN03026A (enExample)
WO (1) WO2014043220A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
WO2013052095A2 (en) 2011-10-03 2013-04-11 Duke University Vaccine
WO2017023857A1 (en) * 2015-08-01 2017-02-09 The Regents Of The University Of California Polypeptide glycopeptide fragments from the v1/v2 and v3 domains of the hiv-1 envelope protein gp 120
CN106800603B (zh) * 2017-01-24 2020-07-28 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法
WO2019018310A1 (en) * 2017-07-19 2019-01-24 The Regents Of The University Of California MGAT1-IMPROVED CELLS FOR THE PRODUCTION OF VACCINES AND BIOPHARMACEUTICAL PRODUCTS
US20210317168A1 (en) * 2018-10-15 2021-10-14 The Regents Of The University Of California Complement Component 1s (C1s) Deficient Cells for Production of Vaccines and Biopharmaceutical Proteins
WO2020117740A1 (en) * 2018-12-03 2020-06-11 International Aids Vaccine Initiative Recombinant hiv env polypeptides and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1109575A2 (en) * 1998-09-29 2001-06-27 University of Kansas Medical Center Live virus vaccines to protect primates from hiv-1 infection and disease
CA2562385A1 (en) * 2004-04-09 2005-10-20 University Of Manitoba Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
US9782472B2 (en) 2008-10-04 2017-10-10 The Regents Of The University Of California Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
CA2757079C (en) * 2009-04-20 2015-05-19 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2011008863A2 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
EP2588211A4 (en) * 2010-06-30 2014-03-05 Torrey Pines Inst EPS TRIMER-IMMUNOGENIC
EP2788026A4 (en) 2011-12-05 2015-08-05 Univ Duke V1V2 IMMUNOGENIC

Also Published As

Publication number Publication date
AU2013315631A1 (en) 2015-04-30
AU2013315631B2 (en) 2018-04-19
CA2929937C (en) 2020-01-07
US20150246111A1 (en) 2015-09-03
US9731002B2 (en) 2017-08-15
US10507239B2 (en) 2019-12-17
CN106170296A (zh) 2016-11-30
CA2929937A1 (en) 2014-03-20
WO2014043220A3 (en) 2016-10-27
EP2928492A2 (en) 2015-10-14
EP2928492A4 (en) 2017-09-13
WO2014043220A2 (en) 2014-03-20
US20180036401A1 (en) 2018-02-08

Similar Documents

Publication Publication Date Title
IN2015DN03026A (enExample)
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
IN2014KN00848A (enExample)
PH12015500390B1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
MX2018010572A (es) Inmunoglobulinas heterodimericas.
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
IN2014CN02100A (enExample)
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
PH12013501849A1 (en) Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
MX365382B (es) Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
WO2013016468A3 (en) Compositions and methods for improving potency and breadth or hiv antibodies
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
NZ717399A (en) Antibodies against csf-1r
MX340683B (es) Anticuerpos anti-vla-4.
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
WO2013090644A3 (en) Anti-hiv antibodies having increased potency and breadth
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
ZA201307529B (en) Truncated hiv envelope proteins (env), methods and compositions related thereto
IN2014CN02963A (enExample)